FDA Approves Roche’s Tecentriq for Stage III dMMR Colon Cancer: A Major Immunotherapy Breakthrough
The FDA approved Roche’s Tecentriq (atezolizumab) for Stage III dMMR colon cancer as adjuvant treatment, cutting recurrence risk by 50% (HR 0.50) in the ATOMIC Phase 3 trial. Priority Review,…